Literature DB >> 23399900

Malignant peripheral nerve sheath tumor invasion requires aberrantly expressed EGF receptors and is variably enhanced by multiple EGF family ligands.

Stephanie J Byer1, Nicole M Brossier, Lafe T Peavler, Jenell M Eckert, Stacey Watkins, Kevin A Roth, Steven L Carroll.   

Abstract

Aberrant epidermal growth factor receptor (EGFR) expression promotes the pathogenesis of malignant peripheral nerve sheath tumors (MPNSTs), the most common malignancy associated with neurofibromatosis type 1, but the mechanisms by which EGFR expression promotes MPNST pathogenesis are poorly understood. We hypothesized that inappropriately expressed EGFRs promote MPNST invasion and found that these kinases are concentrated in MPNST invadopodia in vitro. Epidermal growth factor receptor knockdown inhibited the migration of unstimulated MPNST cells in vitro, and exogenous EGF further enhanced MPNST migration in a substrate-specific manner, promoting migration on laminin and, to a lesser extent, collagen. In this setting, EGF acts as a chemotactic factor. We also found that the 7 known EGFR ligands (EGF, betacellulin, epiregulin, heparin-binding EGF, transforming growth factor-α [TGF-α], amphiregulin, and epigen) variably enhanced MPNST migration in a concentration-dependent manner, with TGF-α being particularly potent. With the exception of epigen, these factors similarly promoted the migration of nonneoplastic Schwann cells. Although transcripts encoding all 7 EGFR ligands were detected in human MPNST cells and tumor tissues, only TGF-α was consistently overexpressed and was found to colocalize with EGFR in situ. These data indicate that constitutive EGFR activation, potentially driven by autocrine or paracrine TGF-α signaling, promotes the aggressive invasive behavior characteristic of MPNSTs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23399900      PMCID: PMC3579504          DOI: 10.1097/NEN.0b013e3182859939

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  31 in total

Review 1.  Foot and mouth: podosomes, invadopodia and circular dorsal ruffles.

Authors:  Roberto Buccione; James D Orth; Mark A McNiven
Journal:  Nat Rev Mol Cell Biol       Date:  2004-08       Impact factor: 94.444

2.  Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models.

Authors:  J E DeClue; S Heffelfinger; G Benvenuto; B Ling; S Li; W Rui; W C Vass; D Viskochil; N Ratner
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

3.  Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.

Authors:  Lu Q Le; Chiachi Liu; Tracey Shipman; Zhiguo Chen; Ueli Suter; Luis F Parada
Journal:  Cancer Res       Date:  2011-05-06       Impact factor: 12.701

4.  Malignant peripheral nerve sheath tumours in neurofibromatosis 1.

Authors:  D G R Evans; M E Baser; J McGaughran; S Sharif; E Howard; A Moran
Journal:  J Med Genet       Date:  2002-05       Impact factor: 6.318

5.  Constitutive activation of the neuregulin-1/ErbB receptor signaling pathway is essential for the proliferation of a neoplastic Schwann cell line.

Authors:  Paul W Frohnert; Mark S Stonecypher; Steven L Carroll
Journal:  Glia       Date:  2003-08       Impact factor: 7.452

Review 6.  Neurofibroma and schwannoma.

Authors:  Rosalie E Ferner; Michael J O'Doherty
Journal:  Curr Opin Neurol       Date:  2002-12       Impact factor: 5.710

7.  Lysophosphatidic acid promotes the proliferation of adult Schwann cells isolated from axotomized sciatic nerve.

Authors:  Paul W Frohnert; Mark S Stonecypher; Steven L Carroll
Journal:  J Neuropathol Exp Neurol       Date:  2003-05       Impact factor: 3.685

8.  Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms.

Authors:  Arie Perry; Sarah N Kunz; Christine E Fuller; Ruma Banerjee; Edith F Marley; Helen Liapis; Mark A Watson; David H Gutmann
Journal:  J Neuropathol Exp Neurol       Date:  2002-08       Impact factor: 3.685

9.  Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model.

Authors:  Hongzhen Li; Susana Velasco-Miguel; William C Vass; Luis F Parada; Jeffrey E DeClue
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

10.  Migration by haptotaxis of a Schwann cell tumor line to the basement membrane glycoprotein laminin.

Authors:  J B McCarthy; S L Palm; L T Furcht
Journal:  J Cell Biol       Date:  1983-09       Impact factor: 10.539

View more
  5 in total

1.  Classic Ras Proteins Promote Proliferation and Survival via Distinct Phosphoproteome Alterations in Neurofibromin-Null Malignant Peripheral Nerve Sheath Tumor Cells.

Authors:  Nicole M Brossier; Amanda M Prechtl; Jody Fromm Longo; Stephen Barnes; Landon S Wilson; Stephanie J Byer; Stephanie N Brosius; Steven L Carroll
Journal:  J Neuropathol Exp Neurol       Date:  2015-06       Impact factor: 3.685

Review 2.  Structure and function of epigen, the last EGFR ligand.

Authors:  Marlon R Schneider; Yosef Yarden
Journal:  Semin Cell Dev Biol       Date:  2013-12-25       Impact factor: 7.727

3.  Identification of candidate genes for devil facial tumour disease tumourigenesis.

Authors:  Robyn L Taylor; Yiru Zhang; Jennifer P Schöning; Janine E Deakin
Journal:  Sci Rep       Date:  2017-08-18       Impact factor: 4.379

4.  ErbB4 promotes malignant peripheral nerve sheath tumor pathogenesis via Ras-independent mechanisms.

Authors:  Jody Fromm Longo; Stephanie N Brosius; Laurel Black; Stuart H Worley; Robert C Wilson; Kevin A Roth; Steven L Carroll
Journal:  Cell Commun Signal       Date:  2019-07-10       Impact factor: 7.525

Review 5.  Targeting Glioblastoma Stem Cells: A Review on Biomarkers, Signal Pathways and Targeted Therapy.

Authors:  Xuejia Tang; Chenghai Zuo; Pengchao Fang; Guojing Liu; Yongyi Qiu; Yi Huang; Rongrui Tang
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.